Eli Lilly faces a significant period in the first half of 2026, driven by two major clinical milestones. Both events are scheduled for March.
The first milestone is the PDUFA date for orforglipron, its oral GLP-1 obesity treatment. This date is set for March. The drug’s potential launch is expected to be a key event, potentially setting the pricing tone for similar oral therapies.
Eli Lilly also anticipates top-line data from its Phase III TRAILRUNNER-ALZ 1 study. This study evaluates remternetug, a next-generation Alzheimer’s disease treatment. Results are also anticipated in March. Analysts closely watch this readout, considering it one of the most anticipated events in Alzheimer’s research that could reshape the therapeutic landscape.